BD Announces Investments for its U.S. Manufacturing Network

On Jan. 15, BD (Becton, Dickinson and Company), a global medical technology company, announced additional investments in its U.S. manufacturing network. The investments aim “to add capacity for critical medical devices, including syringes, needles and IV catheters, to meet the ongoing needs of the nation's healthcare system.”

A press release on the announcement stated, “As part of the company's 2024 investment of more than $10 million to expand manufacturing capacity, new needle and syringe production lines have been installed at the BD plants in Connecticut and Nebraska. One line is already fully operational with additional lines expected to start up in the coming months.”

Further, “These new lines will boost BD's capacity of domestically manufactured safety-engineered injection devices by more than 40% and conventional syringes by more than 50%, adding hundreds of millions of units annually to support critical U.S. healthcare delivery such as hospital procedures, vaccinations, medication preparation and drug delivery to patients. In addition, BD has hired more than 215 full-time employees at its facilities in Nebraska and Connecticut to support the increased production.”

Additionally, the press release added that BD has plans for more than $30 million in investments to expand IV manufacturing at its plant in Utah.